Hrushikesh Dudhane

The global “transplantation market” size is expected to reach USD 14.67 billion by 2028, exhibiting a CAGR of 10.6% during the forecast period. The increasing awareness regarding organ donations coupled with government initiatives can have an excellent impact on the global market in the forthcoming years, states Fortune Business Insights, in a report, titled “Transplantation Market, 2021-2028.” The market size stood at USD 5.47 billion in 2020. An Overview of the Impact of COVID-19 on this Market The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. Click here to know more: https://www.fortunebusinessinsights.com/transplantation-market-105049 Acquisition of Hawaii Cellular Therapy and Transplant Laboratory (HCTTL) by Eurofins Transplant Diagnostics to Aid Development Eurofins' US Transplant Diagnostics announced the successful acquisition of the Hawaii Cellular Therapy and Transplant Laboratory (HCTTL). HCTTL signed an agreement with Eurofins VRL to enlarge VRL's substantial US geographic footprint. Moreover, the acquisition will improve the long-standing pillar of the Hawaiian transplant community and increase VRL's network of laboratories that are now located in 11 states. It will serve Organ Procurement Organizations, Tissue Banks, and commercial companies needing testing donated biological materials. The merger is expected to push this market's growth due to the transplant network and Eurofins Transplant Diagnostics’ strategies to strengthen its position in the transplantation market. The joint transplant diagnostics portfolio of Viracor-Eurofins laboratory and Transplant Genomics innovative testing of subclinical rejection detection testing will advance Eurofins' US Transplant Diagnostics and transplant care. Request a Sample Copy of the Research Report https://www.fortunebusinessinsights.com/enquiry/sample/transplantation-market-105049 Increasing Cases of Chronic Diseases to Aid Development The surging cases of chronic diseases such as cancer, kidney failure, COPD, lupus, and others will spur the market's opportunities in the foreseeable future. According to the American Lung Association, over 9 million adults over than age of 18 suffered from chronic bronchitis in the U.S in the year 2018, with over 200,000 new cases of lung cancer was recorded in the U.S. Furthermore, the increasing number of cases of organ failures has surged the demand for transplant procedures, which, in turn, will aid the growth of the market. According to the American Journal of Lung Transplantation the number of lung transplant surgeries in the U.S reached record high of more than 200 in the year 2017. There was an increase of 133 lung transplants from the previous year. Quick Buy Transplantation Market https://www.fortunebusinessinsights.com/checkout-page/105049 The Hospital Segment to Hold a Significant Share Based on product type, the market is classified into tissue products, immunosuppressive drugs, and preservation solutions. The tissue segment is expected to account for the largest due to the advent of new, improved outcomes, including Chondrofix Osteochondral Allograft, DeNovo NT Graft, DuraMatrix Collagen Dura Substitute Membrane. Based on application, the market is divided into organ transplant and tissue transplant. The tissue transplant segment is expected to account for the highest transplantation market share in the market during the forecast period. Based on end-users, the market is classified into hospitals, transplantation centers, and others. The hospital segment is expected to hold the lion’s share due to the more significant number of transplants in these facilities. Geographically, the market is classified into North America, Asia Pacific, Europe, Latin America, and the Middle East, and Africa. North America to Lead the Market The market size in North America stood at USD 2.29 billion in 2020. The growth is attributable to the well-established healthcare infrastructure in the US. Asia Pacific is expected to experience the highest CAGR due to the growing number of chronic diseases coupled with the rising geriatric populace. Europe is expected to hold a significant share due to increasing R&D investments by companies. Have Any Query? Ask Our Experts https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/transplantation-market-105049

Rising demand for Therapeutics segment is prognosticated to emerge dominant among various applications in the global Antithrombin Market, finds Fortune Business Insights in a new study. The study is titled “Antithrombin Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2026.” According to the study, the global antithrombin market will exhibit a steady CAGR of 4.1% to reach a value of US$ 725.2 Mn by 2026 from US$ 490.4 Mn in 2018. Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antithrombin-market-100470 According to the U.S. Department of Health and Human services in 2018, antithrombin deficiency is likely to occur about 1 in every 2000 person globally. The fact that antithrombin combines with heparin and can be used for treating congenital antithrombin III deficiency is expected to boost the market in the long run. Increasing Prevalence of Hereditary Antithrombin Deficiency to Boost Market The rising prevalence of medical conditions such as sepsis, hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and extracorporeal membrane oxygenation (ECMO) is creating lucrative growth opportunities for the antithrombin market. Among various application types, the therapeutics segment is anticipated to lead the market with a rising number of antithrombin deficiency cases. In 2018, the therapeutics segment accounted for about 95.7% market share and is likely to continue its dominance in the future as Fortune Business Insights analysts say. However, the high treatment cost of antithrombin may cause end users to opt for cheaper alternatives or supplements. This may hamper the market globally. Again, the developing countries of Asia Pacific may directly opt out of adopting antithrombin treatment because of the high price of this treatment. This may pose a challenge for market players to generate revenue from this region, thus, hampering the overall profit percentage of the market. The Asia Pacific to Emerge as the Fastest Growing Region, with Rising Disposable Incomes Geographically, the global antithrombin market is anticipated to be showing the fastest growth in the Asia Pacific. In 2018, the antithrombin market earned about US$ 179.7 Mn from the Asia Pacific alone. A major reason behind this growth is the fact that developing nations such as India and China are adopting new treatment procedures and techniques to fight back various diseases. The rise in disposable incomes of people in developing nations and their increasing ability to spend more on healthcare and medical aid will create lucrative growth opportunities for the market in the Asia Pacific. Again, Europe is expected to have huge potential for growth for antithrombin market during the forecast period. This is because countries such as the UK, Germany, France, and others are considerably adopting human antithrombin based products on a large scale. The global antithrombin market is expected to be dominated by three major companies namely SCL Behring, Grifols, and the Shire. In 2018, these three companies together accounted for the highest market share among others. They offer the most commonly used human antithrombin based anticoagulants. Besides, they also have a strong distribution network that makes them have the lion’s share. Other players are focusing on launching cheaper antithrombin products in order to be in the competition. They are also investing huge sums for research and development activities in order to develop new products. Some other companies are entering into collaborations with other companies in order to stay in the competition. Other companies operating in the global antithrombin market are Scripps Laboratories Inc., Octapharma AG, CSL Limited, Grifols, Lee Biosolutions, Kedrion S.p.A., Shire Plc., and LFB USA. Get Customization: https://www.fortunebusinessinsights.com/enquiry/customization/antithrombin-market-100470

Exhibiting a high prevalence for rheumatoid arthritis, North America is forecast to lead the global “rheumatoid arthritis therapeutics market” in a recent report. In a report, titled “RHEUMATOID ARTHRITIS THERAPEUTICS: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2018-2025”, Fortune Business Insights identifies numerous factors enabling growth in the market. According to the report, the global rheumatoid arthritis therapeutics market is anticipated to exhibit 4.6% CAGR and reach valuation of US$ 33,958.4 Mn in 2025 from US$ 23,822.5 Mn in 2017. Request a Sample Copy of the Research Report https://www.fortunebusinessinsights.com/enquiry/sample/rheumatoid-arthritis-therapeutics-market-100488 North America to Lead Global Market with Rising Prevalence of Rheumatoid Arthritis The North America market was worth US$ 9,929.6 Mn in 2017. It is expected to show steady rise owing to the rising prevalence of rheumatoid arthritis and increasing awareness about this disorder. Adding to that, governments of North America are investing huge sums for improving the healthcare and medical facilities in the region. This is helping the rheumatoid arthritis therapeutics market to grow at an impressive pace in North America.On the other side, the demand for rheumatoid arthritis treatment is likely to grow at a considerable pace in Asia Pacific. This is owing to the entry of new drugs, especially biologics, for the treatment of rheumatoid arthritis in the market. This, coupled with expansion of healthcare and medical infrastructure in emerging nations, is likely to help rheumatoid arthritis therapeutic market in Asia Pacific gain more momentum. Quick Buy Rheumatoid Arthritis Therapeutics Market https://www.fortunebusinessinsights.com/checkout-page/100488 An Overview of the Impact of COVID-19 on this Market: The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. Biologics Segment to Account for Highest Market Share In terms of product type, the biologics segment is anticipated to hold the highest share in the market in terms of revenue during the forecast period. In 2017, the biologics segment held 87.6% of the rheumatoid arthritis therapeutics market. This is because biologics targeting specific components of the immune response system help to slow down the rate of progression of arthritis in the patient. They also help in improving the physical functionality of patients and are cost efficient as compared to other treatment methods, which helps to increase the demand for biologics in the market. Presence of expensive drugs for rheumatoid arthritis treatment, coupled with, favorable reimbursement policies are factors propelling the global market. Developing countries are making efforts to improve their medical infrastructure in order to provide medical aid for diseases such as chronic arthritis and other chronic diseases and this is another key factor helping the market to grow. Increasing Number of Medical Professionals Facilitating Rheumatoid Arthritis Treatment Rise in geriatric population is a key factor enabling growth in the market. The prevalence of arthritis is considerably high among aged population, which is why a rise in their number is expected to bode well for the overall market. In case of rheumatoid arthritis, improvement in diagnostic procedures is favoring growth of the global market for rheumatoid arthritis. Furthermore, the market is expected to gain from the spread of various awareness programs and increasing number of skilled healthcare professionals. In 2017, AbbVie Inc., emerged dominant in the global rheumatoid arthritis therapeutics market. At present there are numerous market players operating in the market, out of which about ten players hold 80% of the market. In order to gain competitive advantage, some of the leading companies are focusing on investing increasingly towards research and development of novel therapeutics. Some of the other key players operating in the global rheumatoid arthritis therapeutics market are Gilead Sciences, Inc. Hoffmann-La Roche AG Eli Lilly and Company UCB S.A. Bristol-Myers Squibb Company Amgen Inc., Pfizer Inc. Celgene Corporation Johnson & Johnson Services, Inc. Have Any Query? Ask Our Experts https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/rheumatoid-arthritis-therapeutics-market-100488 Key Segments Within the Market By Product Type Biologics Non-Biologics Non-Steroidal Anti-Inflammataory Drugs (NSAIDs) Synthetic Disease-Modifying Antirheumatic Drugs (sDMARDs) By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy By Geography North America (USA and Canada) Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe) Asia Pacific (China, India, Japan, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (GCC Countries, South Africa, Rest of Middle East & Africa)

The global “hepatitis C drugs market” will derive growth impetus from the high prevalence of hepatitis C across the world. According to a report published by Fortune Business Insights, titled “Hepatitis C Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 7,866.6 Mn in 2018. Fortune Business Insights states that the market is projected to reach US$ 7,351.7 Mn by 2026, exhibiting a CAGR of -0.9% in the forecast period. Hepatitis C requires oral injections and dosages on a weekly basis, and it also has several side effects that can also lead to permanent damage. Increasing clinical trials and successful drug clearances have aided the overall growth of the global hepatitis C market. Increasing number of regulatory approvals will boost the global hepatitis C market in the forthcoming years. Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the research and development of drugs associated with the treatment of this disease. Several new drugs have been launched in recent times, due to the high prevalence of hepatitis C across the world. Request a Sample Copy of the Research Report https://www.fortunebusinessinsights.com/enquiry/sample/hepatitis-c-drug-market-101562 Huge Hepatitis C Patient Pool Will Offer Growth Opportunities for the Market in North America The high prevalence of hepatitis C has created a need for efficient drugs at low cost. Fortune Business Insights has identified increasing hepatitis C incidence as a primary growth driver. The increased adoption of hepatitis C drugs will favor the growth of the market in North America. Fortune Business Insights has predicted that the hepatitis C drugs market in North America will witness considerable growth, driven by the high demand for hepatitis C drugs. Furthermore, recent drug advancements will fuel the demand for related drugs, subsequently aiding market growth. Fortune Business Insights states that the hepatitis C drugs market in North America was valued at US$ 3,736.6 Mn in 2018. Fortune Business Insights profiles a few of the prominent companies that are operating in the global market. Some of the leading companies that have established standout market positions are AbbVie Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd, and Vertex Pharmaceuticals Incorporated. Click here to know more: https://www.fortunebusinessinsights.com/industry-reports/hepatitis-c-drug-market-101562

Exhibiting a high prevalence for rheumatoid arthritis, North America is forecast to lead the global “rheumatoid arthritis therapeutics market” in a recent report. In a report, titled “RHEUMATOID ARTHRITIS THERAPEUTICS: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2018-2025”, Fortune Business Insights identifies numerous factors enabling growth in the market. According to the report, the global rheumatoid arthritis therapeutics market is anticipated to exhibit 4.6% CAGR and reach valuation of US$ 33,958.4 Mn in 2025 from US$ 23,822.5 Mn in 2017. Request a Sample Copy of the Research Report https://www.fortunebusinessinsights.com/enquiry/sample/rheumatoid-arthritis-therapeutics-market-100488 North America to Lead Global Market with Rising Prevalence of Rheumatoid Arthritis The North America market was worth US$ 9,929.6 Mn in 2017. It is expected to show steady rise owing to the rising prevalence of rheumatoid arthritis and increasing awareness about this disorder. Adding to that, governments of North America are investing huge sums for improving the healthcare and medical facilities in the region. This is helping the rheumatoid arthritis therapeutics market to grow at an impressive pace in North America.On the other side, the demand for rheumatoid arthritis treatment is likely to grow at a considerable pace in Asia Pacific. This is owing to the entry of new drugs, especially biologics, for the treatment of rheumatoid arthritis in the market. This, coupled with expansion of healthcare and medical infrastructure in emerging nations, is likely to help rheumatoid arthritis therapeutic market in Asia Pacific gain more momentum. Click here to know more: https://www.fortunebusinessinsights.com/industry-reports/rheumatoid-arthritis-therapeutics-market-100488 An Overview of the Impact of COVID-19 on this Market: The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. Biologics Segment to Account for Highest Market Share In terms of product type, the biologics segment is anticipated to hold the highest share in the market in terms of revenue during the forecast period. In 2017, the biologics segment held 87.6% of the rheumatoid arthritis therapeutics market. This is because biologics targeting specific components of the immune response system help to slow down the rate of progression of arthritis in the patient. They also help in improving the physical functionality of patients and are cost efficient as compared to other treatment methods, which helps to increase the demand for biologics in the market. Presence of expensive drugs for rheumatoid arthritis treatment, coupled with, favorable reimbursement policies are factors propelling the global market. Developing countries are making efforts to improve their medical infrastructure in order to provide medical aid for diseases such as chronic arthritis and other chronic diseases and this is another key factor helping the market to grow. Increasing Number of Medical Professionals Facilitating Rheumatoid Arthritis Treatment Rise in geriatric population is a key factor enabling growth in the market. The prevalence of arthritis is considerably high among aged population, which is why a rise in their number is expected to bode well for the overall market. In case of rheumatoid arthritis, improvement in diagnostic procedures is favoring growth of the global market for rheumatoid arthritis. Furthermore, the market is expected to gain from the spread of various awareness programs and increasing number of skilled healthcare professionals. In 2017, AbbVie Inc., emerged dominant in the global rheumatoid arthritis therapeutics market. At present there are numerous market players operating in the market, out of which about ten players hold 80% of the market. In order to gain competitive advantage, some of the leading companies are focusing on investing increasingly towards research and development of novel therapeutics. Some of the other key players operating in the global rheumatoid arthritis therapeutics market are Gilead Sciences, Inc. Hoffmann-La Roche AG Eli Lilly and Company UCB S.A. Bristol-Myers Squibb Company Amgen Inc., Pfizer Inc. Celgene Corporation Johnson & Johnson Services, Inc.

Rising demand for novel therapeutics among aging population will enable growth in the Global Glaucoma Therapeutics Market. Recently Fortune Business Insights has published a report, titled “Glaucoma Therapeutics: Global Market Analysis, Insights and Forecast, 2019-2026.” According to the report, in 2018 the global market was worth US$ 6273.5 Mn. However, the global market is anticipated to expand at a CAGR of 6.1% and reach US$ 10,091 Mn by the end of 2026. The report also classifies the market on the basis of various segments. According to the report Glaucoma Therapeutics Market in North America was worth US$ 2405.9 Mn in 2018. The region is expected to dominate the global market during the forecast period 2019-2026. The growth predicted in North America is attribute to its constantly improving healthcare facilities and adoption of recent advances in glaucoma diagnosis, treatment, and medication. These factors also are expected to bode well for the global glaucoma therapeutics market. Meanwhile, the increasing number of glaucoma cases in nations such as China and India is projected to enable growth in Asia Pacific. Additionally, the region is anticipated to progress at a relatively high CAGR. Browse Complete Report Details@: https://www.fortunebusinessinsights.com/industry-reports/glaucoma-therapeutics-market-100312 “Public authorities and governments are adoption several initiatives to create awareness about glaucoma and aid in the cure and prevention of glaucoma. This is projected to generate demand in the market,” said a lead analyst at Fortune Business Insights. Key Segmentation By Drug Class Beta Blockers Prostaglandins Latanoprost Bimatoprost Travoprost Others Alpha Adrenergic Agonists Carbonic Anhydrase Inhibitors Combination Drugs Others By Disease Indication Open Angle Glaucoma Angle Closure Glaucoma Others By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Prostaglandins to Remain Dominant among Drug Class Through Forecast Period In terms of drug class, prostaglandins are the most widely used medication. Additionally, in 2018 the prostaglandins segment was dominating the global glaucoma therapeutics market. The segment accounted for 40.2% of the global market in 2018. Prostaglandins are forecast to dominate the global market during the forecast period as well. Higher efficiency to reduce intraocular pressure (IOP) and minimal risk of side effects associated with the drugs are a few factors aiding the expansion of the prostaglandins segment. Get PDF Brochure of this Report@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/glaucoma-therapeutics-market-100312